{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:53:15Z","timestamp":1782247995580,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1187,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/jto.0b013e31825f22ee","type":"journal-article","created":{"date-parts":[[2012,8,15]],"date-time":"2012-08-15T08:53:52Z","timestamp":1345020832000},"page":"1449-1456","source":"Crossref","is-referenced-by-count":79,"title":["A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"7","author":[{"given":"Anna K.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenette","family":"Creaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn J.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Hasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatha","family":"van der Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur W.","family":"Musk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31825f22ee_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib2","article-title":"A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC","volume":"23","author":"van Meerbeeck","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s004280050388","article-title":"Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma","volume":"435","author":"K\u00f6nig","year":"1999","journal-title":"Virchows Arch"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib4","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.10996","article-title":"Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops","volume":"104","author":"Masood","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000029460","article-title":"Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma","volume":"67","author":"K\u00f6nig","year":"2000","journal-title":"Respiration"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib8","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","article-title":"The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib9","first-page":"601","article-title":"Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors","volume":"2","author":"Versnel","year":"1988","journal-title":"Oncogene"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1096-9896(199602)178:2<151::AID-PATH425>3.0.CO;2-E","article-title":"Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo","volume":"178","author":"Langerak","year":"1996","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1165\/ajrcmb.24.6.4334","article-title":"Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo","volume":"24","author":"Metheny-Barlow","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib12","doi-asserted-by":"crossref","first-page":"46706","DOI":"10.1074\/jbc.M406696200","article-title":"Induction of stem cell factor\/c-Kit\/slug signal transduction in multidrug-resistant malignant mesothelioma cells","volume":"279","author":"Catalano","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/01.MP.0000083647.69123.5C","article-title":"c-Kit is not expressed in malignant mesothelioma","volume":"16","author":"Horvai","year":"2003","journal-title":"Mod Pathol"},{"issue":"Suppl 10","key":"10.1097\/JTO.0b013e31825f22ee_bib14","doi-asserted-by":"crossref","first-page":"x3","DOI":"10.1093\/annonc\/mdm408","article-title":"A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities","volume":"18","author":"Christensen","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib15","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ejca.2009.02.022","article-title":"Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines","volume":"45","author":"Nutt","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib16","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1158\/1078-0432.CCR-09-1980","article-title":"E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles","volume":"15","author":"Ikuta","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"Deprimo","year":"2007","journal-title":"J Transl Med"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib18","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","article-title":"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy","volume":"104","author":"Ebos","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib19","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1078-0432.CCR-06-0919","article-title":"Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor","volume":"13","author":"Norden-Zfoni","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1359-6349(05)81009-2","article-title":"FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate","volume":"3","author":"Van den Abbele","year":"2005","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1097\/JTO.0b013e31825f22ee_bib23","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1378\/chest.07-0013","article-title":"Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma","volume":"132","author":"Creaney","year":"2007","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib25","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"suppl","key":"10.1097\/JTO.0b013e31825f22ee_bib26","article-title":"SWOG S0509: a phase II study of novel oral anti-angiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma","volume":"27","author":"Garland","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.7081","article-title":"Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107)","volume":"24","author":"Jahan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.7707","article-title":"Sorafenib in malignant mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307)","volume":"25","author":"Janne","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib29","article-title":"A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM)","volume":"26","author":"Lee","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib30","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib31","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-006-0243-4","article-title":"Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma","volume":"59","author":"Porta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.7526","article-title":"Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)","volume":"25","author":"Karrison","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib34","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.7578","article-title":"A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM)","volume":"27","author":"Dowell","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/ki.2009.552","article-title":"Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib","volume":"77","author":"Porta","year":"2010","journal-title":"Kidney Int"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib38","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","article-title":"Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib39","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","article-title":"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study","volume":"27","author":"Zhu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2009.11.011","article-title":"The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer","volume":"117","author":"Steffensen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib41","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib42","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1378\/chest.125.6.2356","article-title":"Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis","volume":"125","author":"Kwek","year":"2004","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"van der Veldt","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib44","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib45","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31825f22ee_bib46","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.bjc.6605346","article-title":"Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer","volume":"101","author":"Novello","year":"2009","journal-title":"Br J Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415329464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415329464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T16:16:53Z","timestamp":1643213813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415329464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1556086415329464"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31825f22ee","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}